<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Oral Cancer News &#187; rash</title>
	<atom:link href="http://oralcancernews.org/wp/tag/rash/feed/" rel="self" type="application/rss+xml" />
	<link>http://oralcancernews.org/wp</link>
	<description>The Oral Cancer Foundation News Archive</description>
	<lastBuildDate>Mon, 06 Feb 2012 22:09:34 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Palifermin decreases severe oral mucositis after radiotherapy</title>
		<link>http://oralcancernews.org/wp/palifermin-decreases-severe-oral-mucositis-after-radiotherapy/</link>
		<comments>http://oralcancernews.org/wp/palifermin-decreases-severe-oral-mucositis-after-radiotherapy/#comments</comments>
		<pubDate>Tue, 14 Jun 2011 17:16:17 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[chemoradiotherapy]]></category>
		<category><![CDATA[duration]]></category>
		<category><![CDATA[dysgeusia]]></category>
		<category><![CDATA[flushing]]></category>
		<category><![CDATA[growth factor]]></category>
		<category><![CDATA[Kepivance]]></category>
		<category><![CDATA[mucositis]]></category>
		<category><![CDATA[nausea]]></category>
		<category><![CDATA[palifermin]]></category>
		<category><![CDATA[rash]]></category>
		<category><![CDATA[recombinant]]></category>
		<category><![CDATA[vomiting]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=11255</guid>
		<description><![CDATA[Source: www.drbicuspid.com Author: Will Boggs, MD Palifermin (Kepivance) helps reduce the rate, severity, and duration of severe oral mucositis in head and neck cancer patients receiving chemoradiotherapy, two new studies show. &#8220;Combined data from both studies consistently indicated that palifermin has activities against radiochemotherapy-induced mucositis,&#8221; said Dr. Quynh-Thu Le, who led one of the studies, [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/palifermin-decreases-severe-oral-mucositis-after-radiotherapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rash prediction in lung cancer?</title>
		<link>http://oralcancernews.org/wp/rash-prediction-in-lung-cancer/</link>
		<comments>http://oralcancernews.org/wp/rash-prediction-in-lung-cancer/#comments</comments>
		<pubDate>Wed, 26 Jan 2011 15:09:24 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[biomarker]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[rash]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=10317</guid>
		<description><![CDATA[Source: www.medscape.com Author: Maurie Markman, MD Hello. I am Dr. Maurie Markman from Cancer Treatment Centers of America in Philadelphia. I wanted to briefly discuss with you a very interesting paper[1] that appeared online in The Lancet Oncology on December 20th, 2010, and will be in print soon. The paper was entitled &#8220;First-Cycle Rash and [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/rash-prediction-in-lung-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Presence of rash associated with improved survival in patients receiving adjuvant Erbitux® for locally advanced head and neck cancer</title>
		<link>http://oralcancernews.org/wp/presence-of-rash-associated-with-improved-survival-in-patients-receiving-adjuvant-erbitux%c2%ae-for-locally-advanced-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/presence-of-rash-associated-with-improved-survival-in-patients-receiving-adjuvant-erbitux%c2%ae-for-locally-advanced-head-and-neck-cancer/#comments</comments>
		<pubDate>Wed, 18 Nov 2009 02:52:02 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[epithelial growth factory receptor]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[monoclonal antibody]]></category>
		<category><![CDATA[radiotherapy]]></category>
		<category><![CDATA[rash]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=7393</guid>
		<description><![CDATA[Source: professional.cancerconsultants.com Author: staff A multicenter randomized trial has shown that patients with locoregionally advanced head and neck cancer receiving adjuvant Erbitux® (cetuximab) and radiotherapy who develop a rash have a better survival than patients receiving this therapy who don’t develop a rash. The details of this five-year follow-up of a Phase III randomized study [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/presence-of-rash-associated-with-improved-survival-in-patients-receiving-adjuvant-erbitux%c2%ae-for-locally-advanced-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Tips on managing the rash associated with EGFR inhibitors</title>
		<link>http://oralcancernews.org/wp/tips-on-managing-the-rash-associated-with-egfr-inhibitors/</link>
		<comments>http://oralcancernews.org/wp/tips-on-managing-the-rash-associated-with-egfr-inhibitors/#comments</comments>
		<pubDate>Mon, 28 Sep 2009 10:53:00 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[hydrocortisone]]></category>
		<category><![CDATA[Medrol Dosepak]]></category>
		<category><![CDATA[metronidazole cream]]></category>
		<category><![CDATA[rash]]></category>
		<category><![CDATA[secondary superinfection]]></category>
		<category><![CDATA[treatment algorithm]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=6722</guid>
		<description><![CDATA[Source: OncologySTAT (www.oncologystat.com) Author: OncologySTAT Editorial Team Nurses at Duke University Hospital in Durham, NC, have developed a treatment algorithm for the rash that frequently occurs with use of epidermal growth factor receptor (EGFR) inhibitors. “We want to help sustain patients so they can continue to get their therapy and maintain their quality of life,” [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/tips-on-managing-the-rash-associated-with-egfr-inhibitors/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

